Flexing doesn't change that low price fixing schemes, weak incentives and harder regulatory requirements mean pharmaceutical businesses cannot afford to invest in Europe (vs China and USA where they can generate enough profits to fuel R&D). The best thing European leaders can do is allocate more of GDP to fund innovation. They got the message for defense, they should for this, too.
5 Comments